Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 11;7(10):e0246. doi: 10.1097/HC9.0000000000000246

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FSP1 promoted tumor growth and enhanced the resistance to sorafenib-induced ferroptosis in vivo. (A) Colony formations were performed with vehicle or sorafenib (5 μM, 24 h) treated cells. The clones were counted after stained. (B) The subcutaneously implanted tumor samples were obtained by establishing animal models (n = 6/group). Collected the data and protracted the weight and volume growth curves of tumor xenograft samples. (C) Western blot analyses of the expression levels of FSP1 in tumor xenograft samples. (D) Representative images of FSP1 immunohistochemical staining with FSP1 antibodies in indicated groups (×400 magnification). (E and F) The relative levels of MDA and GSH of indicated tumor xenograft samples. The data are the means ± SD of the 3 independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001. Abbreviation: FSP1, ferroptosis suppressor protein 1.